What is Emergent Health Corp?
develops and sells regenerative medicine, neutraceuticals, and phytonutritionals.
EMGE · Verdict
Solid reward · high risk
EMGE stands out on volatility and growth, but watch the balance sheet signal.
Based on 88% data coverage
EMGE · Verdict
Above average
Rev +113.8% CAGR · earnings +174.0%
Above average
Current ratio 0.14
-75% free-cash-flow margin
-100% net margin · -164% ROE
Model-based scoring. For information only — not financial advice.
develops and sells regenerative medicine, neutraceuticals, and phytonutritionals. Its products comprise Vita-Stim, a nutrient that enhances the immune system, nourishes stem cells, and maintains health; Neuvitale, which nourishes stem cells and acts as a methyl donor to protect DNA; Hungarest, a diet aid that controls appetite in the brain and stomach; EmergentO2, water oxygenator, which increases oxygen in the blood stream; and products for reducing facial wrinkles. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 128.09K.
The scoring profile indicates moderate reward potential, with growth and valuation as the leading contributors. Risk indicators are high — this profile reflects meaningful downside exposure.
For informational purposes only. Not financial advice.